<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01985204</url>
  </required_header>
  <id_info>
    <org_study_id>EK 2013-N-24</org_study_id>
    <nct_id>NCT01985204</nct_id>
  </id_info>
  <brief_title>Iodine Supplementation in Obesity</brief_title>
  <official_title>Assessment of the Improvement of the Cardiovascular Risk Profile in Obese Women After Correction of Iodine Deficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Federal Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Swiss Federal Institute of Technology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypothesis is that iodine supplementation will lower serum TSH and leptin
      concentrations and thereby improve the lipid and glucose profile.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be a double blind, placebo controlled intervention study in obese women living
      in the Atlas foot mountains in Morocco, an iodine deficient area. Eligible subjects will be
      randomized into intervention and control group and will receive the respective supplement for
      6 months. At baseline, midpoint and endpoint anthropometric as well as metabolic profile will
      be assessed. A health questionnaire will further be administered monthly when the tablets for
      the following month are distributed. Urine samples to determine iodine status will also be
      collected monthly.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in TSH (thyroid-stimulating hormone)</measure>
    <time_frame>change from baseline to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in fasting insulin</measure>
    <time_frame>change from baseline to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>change in the LDL cholesterol/ HDL cholesterol ratio</measure>
    <time_frame>change from baseline to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma leptin</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>LDL cholesterol</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HDL cholesterol</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary iodine</measure>
    <time_frame>change from baseline to 6 months</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>T3</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>T4</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>total cholesterol</measure>
    <time_frame>baseline, 3 months and 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>TSH</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>leptin</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">162</enrollment>
  <condition>Iodine Deficiency</condition>
  <condition>Subclinical Hypothyroidism</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Iodine tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Iodine tablet</intervention_name>
    <description>Iodine tablets containing 200 ug iodine as potassium iodate</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet without iodine</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women of reproductive age (20 to 50 years)

          -  Body mass index 27 to 40 kg/m2

          -  Having received oral and written information about the aims and procedures of the
             study

          -  Willing to comply with the study procedure

          -  Having provided oral and written informed consent

        Exclusion Criteria:

          -  Chronic disease or gastrointestinal disorders

          -  Nodular goiter

          -  Regular use of medication (except oral contraceptives)

          -  Pregnancy or lactation

          -  Subject who cannot be expected to comply with study protocol
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Aeberli, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ETH Zurich (Switzerland)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universite Caddi Ayad, Faculte de Medecine et de Pharmacie</name>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Cadi Ayyad, Faculte des Sciences</name>
      <address>
        <city>Marrakech</city>
        <country>Morocco</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Morocco</country>
  </location_countries>
  <verification_date>July 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2013</study_first_submitted>
  <study_first_submitted_qc>November 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2013</study_first_posted>
  <last_update_submitted>July 29, 2014</last_update_submitted>
  <last_update_submitted_qc>July 29, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Swiss Federal Institute of Technology</investigator_affiliation>
    <investigator_full_name>Isabelle Aeberli</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>iodine</keyword>
  <keyword>thyroid hormones</keyword>
  <keyword>obesity</keyword>
  <keyword>TSH</keyword>
  <keyword>dyslipidemia</keyword>
  <keyword>insulin resistance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypothyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Iodine</mesh_term>
    <mesh_term>Cadexomer iodine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

